Novartis AG's Phase III Drug for Heart Failure Bombs Trial

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x600-novartis.jpg" NAME"Novartis Phase III Drug for Heart Failure Bombs Trial" ALT"Novartis Phase III Drug for Heart Failure Bombs Trial"March 22, 2017By Mark Terry, BioSpace.com Breaking News StaffBasel, Switzerland... Source:…

Continue ReadingNovartis AG's Phase III Drug for Heart Failure Bombs Trial

Reverse Merger With Gives Cerulean Execs a Parting Gift—Bonuses

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x600-deal.jpg" NAME"Reverse Merger With Dare Bioscience Gives Cerulean Execs a Parting GiftBonuses" ALT"Reverse Merger With Dare Bioscience Gives Cerulean Execs a Parting GiftBonuses"March 22, 2017By Alex Keown, BioSpace.com... Source:…

Continue ReadingReverse Merger With Gives Cerulean Execs a Parting Gift—Bonuses

Biogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x470-biogen.jpg" NAME"Biogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target" ALT"Biogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even…

Continue ReadingBiogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target